{"entity":{"id":"nct03175224","kind":"trial","name":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","aka":[],"tldr":"A phase 2 trial of Vebreltinib in metastatic cancer and thyroid cancer, run by Apollomics Inc., now recruiting.","summary":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is a phase 2 interventional study registered as NCT03175224 by Apollomics Inc., with 497 participants planned, started 2017-09-27 and due to reach its primary completion in 2026-03-30. Interventions recorded: APL-101 Oral Capsules. Conditions listed: Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03175224","url":"https://clinicaltrials.gov/study/NCT03175224"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":["vebreltinib"],"companies":["apollomics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03175224","phase":"2","setting":"Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","sponsor":"Apollomics Inc.","enrolled":497,"outcomes":[]},"route":"/trials/nct03175224/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"drug":[{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/"}],"company":[{"id":"apollomics","kind":"company","name":"Apollomics","route":"/companies/apollomics/"}]}}